Efficacy and safety of Qingfei Paidu Decoction (Granules) in the treatment of COVID-19
Not Applicable
Recruiting
- Conditions
- ovel Coronavirus Pneumonia (COVID-19)
- Registration Number
- ITMCTR2100004270
- Lead Sponsor
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Conform to the Diagnosis and Treatment Protocol for COVID-19 (trial version 4-7).
Exclusion Criteria
Combined with severe primary respiratory disease, or other microbial pneumonia that needs to be identified from 2019-nCOV.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Qingfei Paidu Decoction's antiviral activity against SARS-CoV-2?
How does Qingfei Paidu Decoction compare to standard-of-care treatments for mild-to-moderate COVID-19 in clinical outcomes?
Which biomarkers correlate with improved response to Qingfei Paidu Decoction in patients with SARS-CoV-2 infection?
What are the potential adverse events associated with Qingfei Paidu Decoction in hospitalized COVID-19 patients?
How does Qingfei Paidu Decoction's pharmacological profile compare to other traditional Chinese medicine formulations for respiratory viral infections?